Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma
Published on 7 October 2026
Prof Xavier Leleu speaks to ecancer about updated results from the phase III BENEFIT trial comparing isatuximab plus bortezomib, lenalidomide and dexamethasone (Isa-VRd) with isatuximab plus lenalidomide and dexamethasone (Isa-Rd) in transplant-ineligible newly diagnosed multiple myeloma.
He reports that at approximately four years of follow-up, progression-free survival remained numerically higher with Isa-VRd, although the difference between the treatment groups was not statistically significant.
Prof Leleu highlights a potentially greater benefit among patients with high-risk multiple myeloma, with a 48-month progression-free survival rate of 63.1% with Isa-VRd compared with 40.2% with Isa-Rd.
Long-term modelling also suggests that the progression-free survival benefit of Isa-VRd may become more apparent with longer follow-up, supporting its role as a standard-of-care option for transplant-ineligible patients aged 65–79 years.